Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000265

Drug Information
SynonymsCHEMBL1230609; S1111_Selleck; XL880; GSK1363089; 88Z; GSK 1363089; EC-000.2326; 937176-80-2; XL 880; GSK 089; GSK1363089, GSK089, foretinib, EXEL-2880, XL880
CompanyExelixis / GlaxoSmithKline
IndicationGastric Cancer, Renal Cell Carcinoma, Squamous Cell Cancer of the Head and Neck
[ICD9: 140-229, 151, 189   ICD10: C00-C96, C16, C64]
Phase II    [1]
Solid Tumors
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Phase I    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntineoplastic Agents
PubChem Compound IDCID 42642645.
PubChem Substance IDSID 81082087.
TargetC-Met receptor tyrosine kinaseInhibitor[2][3][4][1][5]
C-Met receptor tyrosine kinaseMultitarget[2][3][4][1][5]
Vascular endothelial growth factor receptor 2Inhibitor[2][3][4][1][5]
Vascular endothelial growth factor receptor 2Multitarget[2][3][4][1][5]
Ref 12011 Pipeline of Exelixis. To Reference
Ref 2Pipeline of EXELIXIS. EXELIXIS. 2009 To Reference
Ref 3MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. Epub 2007 Dec 18. To Reference
Ref 4Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73. To Reference
Ref 5GSK. Product Development Pipeline. February 2009. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543